TrialSignal
Clinical trial intelligence report
A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01587924
Status
COMPLETED
Phase
Phase IIa
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the safety, efficacy, and pharmacokinetics of GSK1278863, a novel treatment for anemia associated with chronic kidney disease, in hemodialysis-dependent subjects. The study involved switching patients from a stable dose of recombinant human erythropoietin (rhEPO) to GSK1278863 over a four-week period.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01587924
Indication
Anaemia
Modality
small molecule
Target
GSK1278863 for anemia in hemodialysis-dependent patients
Intervention
GSK1278863, rhEPO
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.